<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>666</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>14981753</PubmedId>
            <Abstract>Prediction analysis of TH-cell epitopes in the VP3 capsid protein of the hepatitis A virus (HAV) revealed the occurrence of a putative TH epitope in the 102-121 region complying with all the algorithms tested. To confirm these predictions, spleen T lymphocytes obtained from BALB/c mice previously immunised with HAV, were stimulated in vitro with different concentrations of synthetic peptides 102-121 and 110-121 of VP3. The ability of these peptides to stimulate CD4+ T-helper lymphocytes proliferation was evaluated by an immunological flow cytometry detection of bromodeoxyuridine incorporation. Using this method, it is concluded that the amino terminal part of the VP3 102-121 sequence contains a T cell epitope.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>525-32</ArticlePages>
            <ArticleTitle>A novel CD4+ T-helper lymphocyte epitope in the VP3 protein of hepatitis A virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Sánchez</LastName>
                    <ForeName>Glòria</ForeName>
                </Author>
                <Author>
                    <LastName>Pintó</LastName>
                    <ForeName>Rosa M</ForeName>
                </Author>
                <Author>
                    <LastName>Bosch</LastName>
                    <ForeName>Albert</ForeName>
                </Author>
            </Authors>
            <ArticleChemicalList>Antigens, Viral;Capsid Proteins;Epitopes, T-Lymphocyte;Peptide Fragments;VP3 peptide (110-121), hepatitis A virus;Bromodeoxyuridine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antigens, Viral(immunology); Bromodeoxyuridine(metabolism); Capsid Proteins(immunology); Epitopes, T-Lymphocyte(analysis; chemistry); Hepatitis A virus(immunology); Immunization; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Peptide Fragments(immunology); T-Lymphocytes, Helper-Inducer(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>72</Volume>
                <Issue>4</Issue>
                <Title>Journal of medical virology</Title>
                <Issn>0146-6615</Issn>
                <MedlineTa>J Med Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>VP3(102-121)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASICQMFCFWRGDLVFDFQV</LinearSequence>
                        <StartingPosition>347</StartingPosition>
                        <EndingPosition>366</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P08617.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>12098</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 526</LocationOfData>
                <EpitopeId>4467</EpitopeId>
                <ReferenceStartingPosition>102</ReferenceStartingPosition>
                <ReferenceEndingPosition>121</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3B</LocationOfData>
                        <TCellId>6427</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 weeks old</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>170</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12098</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hepatitis A virus (STRAIN HM-175)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Mice were injected with 3.7 ng of virus particles, diluted 1:2 in Freund's complete adjuvant, in a final volume of 0.2 ml. A booster dose in Freund's incomplete adjuvant was administered 2 weeks later.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>VP3(102-121)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASICQMFCFWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>347</StartingPosition>
                                        <EndingPosition>366</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P08617.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12098</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>200</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>3</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>The percentage of proliferative CD4+ lymphocytes after 10 days of stimulation with peptide was higher than that resulting after 6 days.  The stimulation index, defined as the ratio between the percentage of proliferative CD4+ lymphocytes stimulated with the antigen and the percentage of proliferative CD4+ lymphocytes stimulated with culture medium, was also calculated and shown to produce positive responses in comparison to controls.  Similar results were also shown for a peptide spanning amino acids 110-121 of VP3.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

